Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Qaqish

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The New England Journal of Medicine|June 23, 1988
Unrecognized human immunodeficiency virus infection in emergency department patientsG D Kelen, S Fritz, B Qaqish, et al.
Journal of Medical Virology|June 15, 2018
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II studyImam Waked, Gamal Esmat, Rabab Fouad, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trialTarik Asselah, Christophe Hézode, Roula B Qaqish, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trialImam Waked, Gamal Shiha, Roula B Qaqish, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The New England Journal of Medicine|June 23, 1988
Unrecognized human immunodeficiency virus infection in emergency department patientsG D Kelen, S Fritz, B Qaqish, et al.
Journal of Medical Virology|June 15, 2018
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II studyImam Waked, Gamal Esmat, Rabab Fouad, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trialTarik Asselah, Christophe Hézode, Roula B Qaqish, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trialImam Waked, Gamal Shiha, Roula B Qaqish, et al.
Pageof 3